Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

Robert B. Laprairie; Amina M. Bagher; Jillian L. Rourke; Adel Zrein; Elizabeth A. Cairns; Melanie E.M. Kelly; Christopher J. Sinal; Pushkar M. Kulkarni; Ganesh A. Thakur; Eileen M. Denovan-Wright

doi:10.1016/j.neuropharm.2019.03.033

Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

Robert B. Laprairie, Amina M. Bagher, Jillian L. Rourke, Adel Zrein, Elizabeth A. Cairns, Melanie E.M. Kelly, Christopher J. Sinal, Pushkar M. Kulkarni, Ganesh A. Thakur, Eileen M. Denovan-Wright

Decision Sciences

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Original language	English
Pages (from-to)	1-12
Number of pages	12
Journal	Neuropharmacology
Volume	151
DOIs	https://doi.org/10.1016/j.neuropharm.2019.03.033
Publication status	Published - Jun 2019

ASJC Scopus Subject Areas

Pharmacology
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.neuropharm.2019.03.033

Cite this

Laprairie, R. B., Bagher, A. M., Rourke, J. L., Zrein, A., Cairns, E. A., Kelly, M. E. M., Sinal, C. J., Kulkarni, P. M., Thakur, G. A., & Denovan-Wright, E. M. (2019). Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology, 151, 1-12. https://doi.org/10.1016/j.neuropharm.2019.03.033

Laprairie, RB, Bagher, AM, Rourke, JL, Zrein, A, Cairns, EA, Kelly, MEM , Sinal, CJ, Kulkarni, PM, Thakur, GA & Denovan-Wright, EM 2019, 'Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model', Neuropharmacology, vol. 151, pp. 1-12. https://doi.org/10.1016/j.neuropharm.2019.03.033

@article{d6cd5b0648994e4cb945ded680510337,

title = "Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model",

author = "Laprairie, {Robert B.} and Bagher, {Amina M.} and Rourke, {Jillian L.} and Adel Zrein and Cairns, {Elizabeth A.} and Kelly, {Melanie E.M.} and Sinal, {Christopher J.} and Kulkarni, {Pushkar M.} and Thakur, {Ganesh A.} and Denovan-Wright, {Eileen M.}",

note = "Funding Information: This work was supported by Bridge Funding [Dalhousie University]; the Canadian Institutes of Health Research [MOP-97768]; the National Institutes of Health [DA027113, EY024717]. Studentships from CIHR, the Huntington Society of Canada, Killam Trusts, the Nova Scotia Health Research Foundation, and King AbdulAziz and Dalhousie Universities. The authors thank Kay Murphy for her assistance with animal behaviour and housing. Funding Information: This work was supported by Bridge Funding [Dalhousie University]; the Canadian Institutes of Health Research [ MOP-97768 ]; the National Institutes of Health [ DA027113 , EY024717 ]. Studentships from CIHR, the Huntington Society of Canada , Killam Trusts, the Nova Scotia Health Research Foundation , and King AbdulAziz and Dalhousie Universities. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = jun,

doi = "10.1016/j.neuropharm.2019.03.033",

language = "English",

volume = "151",

pages = "1--12",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

AU - Laprairie, Robert B.

AU - Bagher, Amina M.

AU - Rourke, Jillian L.

AU - Zrein, Adel

AU - Cairns, Elizabeth A.

AU - Kelly, Melanie E.M.

AU - Sinal, Christopher J.

AU - Kulkarni, Pushkar M.

AU - Thakur, Ganesh A.

AU - Denovan-Wright, Eileen M.

N1 - Funding Information: This work was supported by Bridge Funding [Dalhousie University]; the Canadian Institutes of Health Research [MOP-97768]; the National Institutes of Health [DA027113, EY024717]. Studentships from CIHR, the Huntington Society of Canada, Killam Trusts, the Nova Scotia Health Research Foundation, and King AbdulAziz and Dalhousie Universities. The authors thank Kay Murphy for her assistance with animal behaviour and housing. Funding Information: This work was supported by Bridge Funding [Dalhousie University]; the Canadian Institutes of Health Research [ MOP-97768 ]; the National Institutes of Health [ DA027113 , EY024717 ]. Studentships from CIHR, the Huntington Society of Canada , Killam Trusts, the Nova Scotia Health Research Foundation , and King AbdulAziz and Dalhousie Universities. Publisher Copyright: © 2019

PY - 2019/6

Y1 - 2019/6

UR - http://www.scopus.com/inward/record.url?scp=85064221527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064221527&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2019.03.033

DO - 10.1016/j.neuropharm.2019.03.033

M3 - Article

C2 - 30940536

AN - SCOPUS:85064221527

SN - 0028-3908

VL - 151

SP - 1

EP - 12

JO - Neuropharmacology

JF - Neuropharmacology

ER -

Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this